Double-Masked, Dose-Response, Vehicle-Controlled Study of VVN461 Ophthalmic Solution in Postoperative Ocular...

Area of Science:

• Ophthalmology
• Pharmacology

Background:

• Postoperative inflammation is a common complication following cataract surgery.
• Janus kinase (JAK) inhibitors represent a novel therapeutic class for ocular inflammation.

Purpose of the Study:

• To evaluate the safety and ocular efficacy of VVN461, a topical ophthalmic solution, for managing inflammation after cataract surgery.
• To assess the anti-inflammatory potential of VVN461 in a phase II clinical trial.

Main Methods:

• A phase II, multicenter, double-masked, randomized, vehicle-controlled study was conducted.
• Ninety-one subjects undergoing routine unilateral cataract extraction received VVN461 (0.5% or 1.0%) or vehicle four times daily.
• The primary outcome measure was the proportion of subjects with anterior chamber cell grade 0 at day 14.

Main Results:

• VVN461 demonstrated statistically significant efficacy in reducing anterior chamber inflammation (cell grade 0) at day 14 compared to vehicle (60.0% for 1.0% and 53.3% for 0.5% vs. 19.4% for vehicle).
• Treatment with VVN461 also led to a reduced need for rescue medication and decreased anterior chamber flare.
• Adverse events were infrequent and mild in severity in the VVN461 treatment groups.

Conclusions:

• VVN461 exhibits clinically and statistically significant anti-inflammatory efficacy for the treatment of postoperative inflammation following cataract surgery.
• The topical ophthalmic solution demonstrated a favorable safety profile with minimal adverse events.
• VVN461 represents a promising therapeutic option for managing ocular inflammation in the postoperative setting.